Santen EMEA announces RWD on Taptiqom
Taptiqom was efficient in patients with insufficiently controlled open-angle glaucoma (OAG) and ocular hypertension (OHT).
Read More
Tag: open-angle glaucoma
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
